Overview
COLL market data
Price History
COLL price chart
Valuation & Profitability
- P/E (TTM)
- 19.04 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.58 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.71 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 5.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $25.47 – $50.79 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $912.5M · P/B 4.85 · P/S 1.13.
Company News
Collegium Pharma shares are trading higher after the company announced a $50 million accelerated share repurchase program.Benzinga · Aug 13, 2026, 2:50 PM
Collegium Pharmaceutical Announces $50M Accelerated Share Repurchase Agreement With Jefferies, With Initial Delivery Of 1,556,420 Shares; $100M To Remain Under ProgramBenzinga · Aug 13, 2026, 11:32 AM
8-K filing — COLLEGIUM PHARMACEUTICAL, INC (COLL)SEC EDGAR · Aug 13, 2026, 11:30 AM
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43Benzinga · Aug 7, 2026, 5:00 PM
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46Benzinga · Aug 6, 2026, 6:20 PM
Collegium Pharmaceutical shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.Benzinga · Aug 6, 2026, 12:48 PM
Collegium Pharmaceutical Q2 Adj. EPS $1.92 Beats $1.72 Estimate, Sales $199.878M Miss $201.206M EstimateBenzinga · Aug 6, 2026, 11:31 AM
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M EstBenzinga · Aug 6, 2026, 11:31 AM
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jun 5, 2026, 12:15 PM
Collegium to Participate in 2026 Jefferies Global Healthcare ConferenceGlobenewswire Inc · May 27, 2026, 12:15 PM